µ¥Àϸ®ÆÊ-KRPIA,±¹Á¦ ½ÉÆ÷Áö¾ö
µ¥Àϸ®ÆÊ°ú KRPIA´Â ¿À´Ã(23ÀÏ) ¡®±Û·Î¹ú ÀǾàǰ°³¹ß°úÁ¤¿¡¼ Çѱ¹ÀÇ ¿ªÇÒ¡¯À» ÁÖÁ¦·Î ±¹Á¦½ÉÆ÷Áö¾öÀ» °³ÃÖÇÑ´Ù. ±Û·Î¹ú ÀǾàǰ°³¹ß°úÁ¤¿¡¼ 1)IND ½ÂÀοä°Ç ¹× ÀýÂ÷ÀÇ ÇöÀç ¹× Á¦¾ð 2)°¡±³ÀÚ·áÀÇ ¿ä°Ç ¹× ¿î¿µ, ±×¸®°í Á¦¾ð¿¡ ´ëÇØ °¢±¹ÀÇ ¿¬ÀÚµéÀÌ ¹ßÇ¥ÇÏ°í ³íÀÇÇϱâ À§ÇÑ ±¹Á¦±Ô¸ðÀÇ ½ÉÆ÷Áö¾ö. *ÁÖÁ¦ : ±Û·Î¹ú ÀǾàǰ°³¹ß°úÁ¤¿¡¼ Çѱ¹ÀÇ ¿ªÇÒ(Role of Korea in Global Drug Development Symposium) *ÀϽà : 2007³â 11¿ù 23ÀÏ ¿ÀÀü 8½Ã30ºÐ~¿ÀÈÄ 5½Ã *Àå¼Ò : ½ºÀ§½º±×·£µåÈúưȣÅÚ (È«Àºµ¿) ±×·£µåº¼·ë *ÁÖÃÖ : KRPIA Çã°¡µî·ÏÀ§¿øÈ¸ *ÁÖ°ü : µ¥Àϸ®ÆÊ *ÈÄ¿ø : ½ÄǰÀǾàǰ¾ÈÀüû *ŸÀÓ½ºÄÉÁì(¿¬Á¦ ¹× ¿¬»ç)
-08:30-09:00 : Registration µî·Ï
-09:00-09:20 : Opening °³È¸»ç(KFDA/KRPIA Chair
-09:20-09:50 : IND management in Korea = Çѱ¹ÀÇ ÀÓ»ó½ÃÇè°èȹ ½ÂÀÎ °ü¸®ÇöȲ(KFDA, ÁÖ±¤¼ö ÆÀÀå)
-09:50-10:30 : Global drug development: what role will Korea and other Asia countries play in the future? (including future suggestion on bridging data in Korea) = ±Û·Î¹ú ÀǾàǰ°³¹ß¿¡¼ ÇâÈÄ Çѱ¹°ú ´Ù¸¥ ¾Æ½Ã¾Æ ±¹°¡ÀÇ ¿ªÇÒ - ÇâÈÄ Çѱ¹¿¡¼ °¡±³ÀÚ·á¿¡ ´ëÇÑ Á¦¾ð(TBD)
-10:30~11:10 : Overview regulatory procedures for clinical trial applications in Europe including the comparison of data requirements of EU, US and Korea especially in early phases = À¯·´¿¡¼ ÀÓ»ó½ÃÇè½ÅûÀ» À§ÇÑ ±ÔÁ¦°úÁ¤ÀÇ ÀÌÇØ¿Í Ãʱ⠴ܰè ÀÓ»ó½ÃÇèÀ» À§ÇÑ °úÁ¤¿¡ ´ëÇÑ À¯·´, ¹Ì±¹ ¹× Çѱ¹Á¦µµÀÇ ºñ±³(GSK, Ismet Samji)
-11:10-11:30 : Coffee Break
-11:10-11:40 : KFDA experience and improvement in clinical trial application review = ÀÓ»ó½ÃÇè°èȹÀÇ ½É»ç°úÁ¤¿¡¼ ¾òÀº KFDAÀÇ °æÇè°ú °³¼±Á¡(KFDA, ¹Úâ¿ø¿¬±¸°ü)
-11:40-12:00 : Industrial learning and suggestion on IND requirements and procedures in Korea = ÀÓ»ó½ÃÇè½ÂÀÎ ½Åû°úÁ¤¿¡¼ ¾ò¾îÁø ±¹³» Á¦¾à»ê¾÷ÀÇ °æÇè ¹× Á¦¾ð(GSK, À̼ÒÁ¤ ÆÀÀå)
-12:00-13:00 : Lunch
-13:00-13:40 : Accelerated Clinical Development Program through Adaptive Clinical Trial Design = »õ·Î¿î ÀÓ»ó½ÃÇè µðÀÚÀÎ(Adaptive Clinical Trial Design)À» ÅëÇÑ Àӻ󰳹߰úÁ¤ÀÇ °¡¼ÓÈ(BMS, Amit Roy)
-13:40-14:10 : CDE¡¯s perspective in bridging data requirements and procedures in Taiwan = ÀǾàǰ ½ÃÆÇ½ÂÀÎÀ» À§ÇÑ ´ë¸¸¿¡¼ °¡±³ÀÚ·á¿¡ ´ëÇÑ ¿ä°Ç ¹× ÀÌ¿¡ ´ëÇÑ ´ë¸¸ CDEÀÇ ¿î¿µ ¹× ÇâÈÄ Àü¸Á(CDE, Wen-Hsin Chiu)
-14:10-14:40 : PMDA¡¯s perspective in bridging data requirements and procedures in Japan = ÀǾàǰ ½ÃÆÇ½ÂÀÎÀ» À§ÇÑ ÀϺ»¿¡¼ °¡±³ÀÚ·á¿¡ ´ëÇÑ ¿ä°Ç ¹× ÀÌ¿¡ ´ëÇÑ ÀϺ» PMDAÀÇ ¿î¿µ ¹× ÇâÈÄ Àü¸Á(PMDA, UYAMA YASHIASKI)
-14:40-15:10 : Coffee Break
-15:10-15:40 : KFDA experience and future prospect in bridging data review = °¡±³ÀÚ·á ½É»ç°úÁ¤¿¡¼ ¾òÀº KFDA °æÇè ¹× ÇâÈÄ Àü¸Á(KFDA, ¹ÚÀμ÷¿¬±¸°ü)
-15:40-16:10 : lndustrial learning and suggestion on bridging data requirements and procedures in Korea = °¡±³ÀÚ·á Áغñ°úÁ¤¿¡¼ ¾ò¾îÁø ±¹³»Á¦¾à»ê¾÷ÀÇ °æÇè ¹× Á¦¾ð(Pfize, ±èÈñ¼± ºÎÀå)
-16:10-17:00 : Panel Discussion - Simultaneous Global Drug Development = ±¹Á¦Àû ÀǾàǰµ¿½Ã°³¹ß °úÁ¤¿¡¼ Çѱ¹ÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÆÐ³ÎÅäÀÇ(ÁÂÀå, »ç³ëÇÇ ¾Æº¥Æ¼½º µµ¿ø »ó¹«)